Praxis Precision (PRAX) announced that the FDA has accepted for priority review its new drug application for relutrigine, for the treatment of SCN2A and SCN8A developmental and epileptic encephalopathies. The FDA has set a target action date under the Prescription Drug User Fee Act of September 27.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRAX:
- Praxis Precision management to meet with Piper Sandl;er
- Praxis Precision initiated with an Outperform at Wolfe Research
- Praxis Precision Medicines Maps Aggressive Path to Market
- Praxis Precision price target raised to $700 from $500 at Truist
- Praxis Precision price target raised to $130 from $95 at Wedbush